Hidradenitis Suppurativa: A Comprehensive Guide
What is Hidradenitis suppurativa?
Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic inflammatory skin condition that causes painful, recurring nodules and abscesses primarily in areas where skin rubs together, such as the armpits, groin, and buttocks. Despite affecting approximately 1% of the population, HS is frequently underdiagnosed and misunderstood, leading many patients on a difficult diagnostic journey that can span years. The condition predominantly affects women and typically begins after puberty, causing significant physical discomfort and emotional distress. While classified as a rare disease due to frequent underdiagnosis, HS is more common than previously recognized and can profoundly impact quality of life.
Key statistics
| Prevalence | Approximately 1% globally (likely underestimated) |
| Gender ratio | 3:1 female to male predominance |
| Typical age of onset | 20-30 years, after puberty |
| Diagnostic delay | Average 7-10 years from symptom onset |
Symptoms
Primary symptoms: Painful nodules, recurrent abscesses, draining sinus tracts, scarring, malodorous discharge, limited mobility in affected areas.
The hallmark of hidradenitis suppurativa is the development of painful, inflamed nodules that typically appear in areas rich in apocrine sweat glands. These lesions most commonly affect the axillae (armpits), inguinal region (groin), perianal area, and inframammary areas (under the breasts).
Early symptoms often begin with single, tender nodules that may be mistaken for infected hair follicles or simple boils. These lesions can be intensely painful, often described as throbbing or burning. As the condition progresses, patients may experience recurrent flare-ups with multiple nodules appearing simultaneously.
Advanced symptoms include the formation of sinus tracts—tunnels under the skin that connect different lesions and may drain purulent or malodorous fluid. Chronic inflammation leads to significant scarring, which can cause contractures and limited range of motion. The persistent drainage and odor can be particularly distressing, affecting social interactions and self-esteem. Some patients develop hypertrophic scars or keloids, while others may experience systemic symptoms such as fatigue and malaise during severe flare-ups.
Causes and risk factors
Hidradenitis suppurativa has a multifactorial etiology involving genetic, hormonal, and environmental components. Approximately one-third of patients have a family history of the condition, suggesting a strong genetic component. Mutations in genes including NCSTN, PSEN1, and PSENEN have been identified in some familial cases, affecting gamma-secretase and Notch signaling pathways.
Risk factors include obesity, smoking (present in up to 90% of patients), hormonal fluctuations (particularly androgens), and mechanical friction from tight clothing. The condition often worsens during menstruation and may improve during pregnancy, highlighting the role of hormonal influences. Metabolic syndrome, including diabetes and cardiovascular disease, is more common in HS patients. Certain medications and stress may trigger flare-ups in susceptible individuals.
The pathophysiology involves follicular occlusion, bacterial overgrowth, and dysregulated immune responses leading to chronic inflammation. Recent research suggests that HS is fundamentally an autoinflammatory condition rather than a purely infectious process.
Prevention
Since hidradenitis suppurativa has significant genetic components, primary prevention is not always possible. However, several evidence-based strategies can reduce flare-up frequency and severity. Maintaining a healthy weight is crucial, as obesity increases mechanical friction and inflammation. Smoking cessation is essential, as tobacco use is strongly associated with disease severity and poor treatment response.
Gentle skincare practices include using antimicrobial washes, wearing loose-fitting, breathable clothing, and avoiding aggressive scrubbing or shaving in affected areas. Some patients benefit from dietary modifications, particularly reducing dairy and high-glycemic foods, though evidence remains limited.
For individuals with a strong family history, genetic counseling may be appropriate to discuss inheritance patterns and reproductive planning. While genetic testing is available for known mutations, the multifactorial nature of HS limits the predictive value of testing in most cases.
Complications
Without appropriate treatment, hidradenitis suppurativa can lead to severe, life-altering complications. Progressive scarring and contractures may result in permanent limitations in mobility and function. Chronic sinus tracts increase infection risk and may require extensive surgical intervention.
Long-term complications include lymphedema due to chronic inflammation and scarring of lymphatic vessels, particularly in the groin area. Rarely, patients may develop aggressive squamous cell carcinoma within chronic lesions, emphasizing the importance of long-term monitoring.
The psychological impact is profound, with depression and anxiety occurring at higher rates than in the general population. Social isolation, sexual dysfunction, and reduced quality of life are common. Employment may be affected due to pain, mobility limitations, and the unpredictable nature of flare-ups.
Systemic complications include increased cardiovascular disease risk, metabolic dysfunction, and chronic pain syndromes. The chronic inflammatory state may contribute to accelerated atherosclerosis and other inflammatory conditions.
Diagnosis
Diagnosing hidradenitis suppurativa relies primarily on clinical criteria, as no specific laboratory tests or imaging studies are diagnostic. The modified Dessau criteria require recurrence (at least two episodes in six months), typical lesion morphology (painful nodules, sinus tracts, bridged scars), and characteristic locations (axillae, groin, perianal, inframammary areas).
Physical examination should assess disease severity using validated scoring systems such as the Hurley staging system (stages I-III) or the International Hidradenitis Suppurativa Severity Score System (IHS4). Photography may be helpful for monitoring disease progression.
Laboratory tests are generally supportive rather than diagnostic. Elevated inflammatory markers (C-reactive protein, erythrocyte sedimentation rate) may be present during active flares. Bacterial culture of draining lesions can guide antibiotic therapy, though results should be interpreted cautiously as secondary bacterial colonization is common.
Imaging studies, including ultrasound or MRI, may be useful for assessing subcutaneous involvement and planning surgical interventions. Biopsy is rarely necessary but may be considered if malignancy is suspected or diagnosis is uncertain.
Treatment
Treatment of hidradenitis suppurativa requires a multimodal approach tailored to disease severity and individual patient factors. Topical therapies include antimicrobial washes containing chlorhexidine or benzoyl peroxide, and topical antibiotics such as clindamycin.
Systemic antibiotic therapy forms the foundation of medical management, with tetracycline, doxycycline, or combination therapy using clindamycin and rifampin showing efficacy. For severe disease, adalimumab is the first FDA-approved biologic therapy for HS. Newer biologics including secukinumab and bimekizumab have also received approval, targeting different inflammatory pathways.
Additional systemic therapies include metformin for metabolic benefits, hormonal therapies such as spironolactone, and immunosuppressants like cyclosporine or methotrexate in refractory cases.
Surgical intervention may be necessary for severe or refractory disease, ranging from incision and drainage of acute lesions to wide local excision of affected areas. CO2 laser therapy and other advanced surgical techniques show promise for reducing recurrence rates.
Prognosis
The prognosis for hidradenitis suppurativa varies significantly based on disease severity, treatment response, and adherence to management strategies. Early diagnosis and appropriate treatment can substantially improve outcomes and quality of life. With modern therapies, many patients experience significant reduction in flare frequency and pain levels.
However, HS is typically a chronic condition requiring long-term management. Complete remission is uncommon, and patients should expect periods of disease activity interspersed with stable phases. Factors associated with better outcomes include early treatment initiation, smoking cessation, weight management, and adherence to prescribed therapies.
Life expectancy is generally not significantly reduced, though the increased cardiovascular disease risk associated with chronic inflammation warrants monitoring. The greatest impact is on quality of life, with appropriate treatment dramatically improving physical comfort, mobility, and psychological well-being.
Quality of life
Living with hidradenitis suppurativa requires comprehensive lifestyle adaptations and strong support systems. Daily management includes gentle wound care, appropriate dressing changes, and maintaining good hygiene without over-cleansing. Clothing choices should prioritize loose-fitting, breathable fabrics that minimize friction.
Dietary considerations may include avoiding high-glycemic foods and dairy products, though individual responses vary. Regular exercise is beneficial for overall health and weight management, with low-impact activities often better tolerated during flares. Swimming in properly chlorinated pools may be therapeutic for some patients.
Mental health support is crucial, as depression and anxiety are common. Counseling, support groups, and stress management techniques can significantly improve coping strategies. Open communication with employers about condition needs may help maintain employment stability.
Sleep quality often improves with better pain management and treatment of active lesions. Creating a supportive home environment with appropriate seating and bedding can enhance comfort during flare-ups.
Pregnancy and fertility
Hidradenitis suppurativa can impact pregnancy planning and management, though many women successfully conceive and deliver healthy babies. The condition may improve during pregnancy due to hormonal changes, particularly decreased androgen activity. However, some women experience worsening symptoms postpartum.
Medication safety during pregnancy requires careful consideration. Many systemic antibiotics are safe during pregnancy, while biologic therapies require individualized risk-benefit assessment. Adalimumab may be continued during pregnancy with appropriate monitoring, though timing of discontinuation should be discussed with specialists.
Fertility is generally not directly affected by HS, though severe perianal or genital involvement may impact sexual function. Cesarean delivery may be recommended if active lesions are present in the perianal area. Genetic counseling may be appropriate given the hereditary component of the condition.
Children
Pediatric hidradenitis suppurativa is less common but can occur, particularly after puberty. Early recognition is crucial, as delayed diagnosis and treatment can lead to more severe complications and psychological impact during formative years.
Treatment approaches in children are similar to adults but require careful consideration of medication safety and dosing. Biologic therapies may be used in severe pediatric cases with appropriate monitoring. Psychological support and school accommodations may be necessary to address the impact on academic and social development.
Family education and support are essential components of pediatric HS management, helping children develop appropriate self-care skills and coping strategies.
When to see a doctor
Patients should seek medical attention for recurrent, painful nodules in characteristic locations, particularly if lesions fail to resolve with standard care or worsen over time. Urgent medical care is needed for signs of severe infection including fever, rapidly spreading redness, systemic illness, or severe pain requiring narcotic medication.
Routine follow-up should be scheduled for disease monitoring, treatment adjustment, and screening for complications. Patients should also consult healthcare providers before making significant medication changes or if planning pregnancy.
Dermatology referral is appropriate for suspected HS, while plastic surgery consultation may be beneficial for patients requiring surgical intervention.
Regional context
Limited data exists regarding hidradenitis suppurativa prevalence in the Caucasus region, including Georgia, Armenia, and Azerbaijan. The condition likely occurs at similar rates to other populations, though underdiagnosis may be more significant due to limited awareness among healthcare providers and patients.
Cultural factors may influence treatment-seeking behavior and disclosure of symptoms in intimate areas. Healthcare systems in the region may benefit from increased education about HS recognition and management. The Global Medical Journal welcomes regional contributions and research collaborations to better understand HS prevalence and treatment outcomes in Eastern Mediterranean and Caucasus populations.
Research and clinical trials
Current research focuses on novel therapeutic targets, including JAK inhibitors, complement inhibitors, and other immunomodulatory agents. Studies investigating the role of the microbiome in HS pathogenesis may lead to probiotic or other microbiome-targeted therapies.
Recent breakthroughs include the approval of multiple biologic agents and improved understanding of HS as an autoinflammatory condition. Pipeline treatments include oral small-molecule inhibitors and novel surgical techniques.
Patients interested in clinical trials can search ClinicalTrials.gov for current studies. Participation in research studies may provide access to cutting-edge treatments while contributing to scientific understanding of this challenging condition.
Frequently asked questions
Is hidradenitis suppurativa contagious?
No, HS is not contagious. It’s an inflammatory condition with genetic and hormonal components, not an infection that can spread between people.
Can diet changes help manage HS symptoms?
Some patients report improvement with dietary modifications, particularly reducing dairy and high-glycemic foods. However, evidence is limited, and dietary changes should complement, not replace, medical treatment.
Will HS get worse over time?
Disease progression varies among individuals. With appropriate treatment, many patients experience improved symptoms and reduced flare frequency. Early intervention generally leads to better outcomes.
Can I exercise with hidradenitis suppurativa?
Yes, exercise is beneficial for overall health and weight management. Choose low-impact activities and wear breathable, loose-fitting clothing. Shower promptly after exercise and apply appropriate wound care.
Is surgery always necessary for HS?
Surgery is not always required. Many patients respond well to medical therapies. Surgical intervention is typically reserved for severe disease, recurrent abscesses, or when medical therapy fails to provide adequate control.
Support and resources
- HS Foundation: https://www.hs-foundation.org – Dedicated patient advocacy and education organization
- Orphanet: https://www.orpha.net – Rare disease information portal
- EURORDIS: https://www.eurordis.org – European rare disease advocacy
- National Organization for Rare Disorders (NORD): https://rarediseases.org
- International Alliance of Dermatology Patient Organizations: https://iadpo.org
- ClinicalTrials.gov: https://clinicaltrials.gov – Clinical trial search database
Related conditions
- Acne vulgaris – Related inflammatory skin condition
- Pilonidal disease – Similar presentation in sacrococcygeal region
- Crohn’s disease – Associated inflammatory bowel disease
- Pyoder
Cite this page
GMJ News Desk. “Hidradenitis suppurativa.” GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/condition/hidradenitis-suppurativa/
Licensed under CC BY 4.0. Free to share with attribution to GMJ News.Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.
Was this article helpful?